Background: Numeracy is an area of difficulty for children with Down syndrome (DS). It has been demonstrated that The Number Race, a non-commercial adaptive computer game designed to foster basic mathematical abilities, represents a promising instrument to enhance these skills in children with DS when delivered by an expert in a clinical setting.
Aims: In the present study, we assessed the efficacy of The Number Race when administered at home by properly instructed and remotely supervised parents.
Methods And Procedures: Basic numerical skills were assessed before and after training, as well as at three-months follow-up. Performance of children with DS who worked at home with the parent (PG) was compared with that of children who received the training by an expert (EG). For both groups, the training lasted ten weeks, with two weekly sessions of 20-30 min.
Outcomes And Results: Results show that both groups improved across various measures of numerical proficiency, including the overall score of the numeracy assessment battery, while only the EG showed an improvement in a measure of mental calculation. The improvements were maintained three months after the end of the training.
Conclusions And Implications: These findings confirm the efficacy of The Number Race and extend it to an home-based setting, whereby parents administer the training with external supervision.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ridd.2021.103919 | DOI Listing |
Alzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFBackground: evoke and evoke+ are phase 3, randomized, placebo-controlled trials currently investigating the glucagon-like peptide-1 receptor agonist semaglutide as disease-modifying therapy (DMT) in persons with early Alzheimer's disease (AD). How the evoke and evoke+ trial populations compare with other phase 3 programs for DMTs in early AD has not been described.
Method: We compare the inclusion/exclusion criteria and baseline characteristics of the evoke/evoke+ trial populations with those of Clarity AD (lecanemab) and TRAILBLAZER-ALZ-2 (donanemab): two recent phase 3 trials assessing anti-amyloid monoclonal antibodies in persons with early AD.
Alzheimers Dement
December 2024
HealthPartners Institute, Minneapolis, MN, USA.
Background: Cholinesterase inhibitors (ChEIs) are cornerstones in the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VD). Despite their widespread use, patterns of prescribing ChEIs are not fully understood.
Objective: Examine the prevalence, timing, and types of ChEI prescriptions before and after dementia diagnosis including prescribing patterns by patient sex and race.
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA.
Background: In the United States, Black people represent 12% of the total US population and account for 19.3% of dementia cases. Social determinants of health (SDOH) and vascular comorbidities contribute to Black/African Americans having a higher risk of Alzheimer's disease and related dementias (ADRD).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.
Background: Disparities in the quality and timeliness of care for Alzheimer's disease (AD) are well documented. This study assessed the impact of demographic characteristics on the diagnosis and management of early AD patients in community-based settings.
Method: This cross-sectional study abstracted medical chart data for patients aged 50-89 years who had newly diagnosed early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and a clinic visit within the past 12 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!